Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD

J. A. van Noord, R. Buhl, C. LaForce, C. Martin, F. Jones, M. Dolker, T. Overend (Heerlen, Netherlands; Mainz, Germany; Raleigh, East Hanover, United States Of America; Horsham, United Kingdom)

Source: Annual Congress 2009 - Next generation bronchodilators
Session: Next generation bronchodilators
Session type: E-Communication Session
Number: 4347
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. A. van Noord, R. Buhl, C. LaForce, C. Martin, F. Jones, M. Dolker, T. Overend (Heerlen, Netherlands; Mainz, Germany; Raleigh, East Hanover, United States Of America; Horsham, United Kingdom). Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD. Eur Respir J 2009; 34: Suppl. 53, 4347

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Source: Eur Respir J 2011; 37: 273
Year: 2011



24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011



Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009


A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001

Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 14s
Year: 2005